Compare Stocks: TRDA, ANNX, AVTX, and CADL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANNX Annexon	$4.02 +0.5%	$4.65	$2.54 ▼ $7.18	$758.32M	1.32	3.47 million shs	2.39 million shs
AVTX Avalo Therapeutics	$13.65 +1.6%	$17.64	$12.51 ▼ $24.27	$720.25M	0.68	1.21 million shs	648,577 shs
CADL Candel Therapeutics	$9.94 +2.9%	$11.52	$4.35 ▼ $14.00	$739.17M	-0.32	1.20 million shs	718,129 shs
TRDA Entrada Therapeutics	$5.67 +2.5%	$6.81	$5.15 ▼ $16.45	$215.32M	-0.24	330,102 shs	209,364 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANNX Annexon	-0.25%	-2.91%	-14.35%	-31.03%	+26.98%
AVTX Avalo Therapeutics	-1.10%	-10.17%	-31.86%	-30.09%	-5.56%
CADL Candel Therapeutics	-1.63%	-4.92%	-23.33%	+1.79%	+53.33%
TRDA Entrada Therapeutics	-1.43%	-2.64%	-26.46%	-20.09%	-10.23%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANNX Annexon	$4.02 +0.5%	$4.65	$2.54 ▼ $7.18	$758.32M	1.32	3.47 million shs	2.39 million shs
AVTX Avalo Therapeutics	$13.65 +1.6%	$17.64	$12.51 ▼ $24.27	$720.25M	0.68	1.21 million shs	648,577 shs
CADL Candel Therapeutics	$9.94 +2.9%	$11.52	$4.35 ▼ $14.00	$739.17M	-0.32	1.20 million shs	718,129 shs
TRDA Entrada Therapeutics	$5.67 +2.5%	$6.81	$5.15 ▼ $16.45	$215.32M	-0.24	330,102 shs	209,364 shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANNX Annexon	-0.25%	-2.91%	-14.35%	-31.03%	+26.98%
AVTX Avalo Therapeutics	-1.10%	-10.17%	-31.86%	-30.09%	-5.56%
CADL Candel Therapeutics	-1.63%	-4.92%	-23.33%	+1.79%	+53.33%
TRDA Entrada Therapeutics	-1.43%	-2.64%	-26.46%	-20.09%	-10.23%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANNX Annexon	2.40	Hold	$15.29	276.22% Upside
AVTX Avalo Therapeutics	2.85	Moderate Buy	$45.10	230.84% Upside
CADL Candel Therapeutics	2.73	Moderate Buy	$20.14	103.32% Upside
TRDA Entrada Therapeutics	2.50	Moderate Buy	$17.75	215.00% Upside

Current Analyst Ratings Breakdown

Latest TRDA, ANNX, AVTX, and CADL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/2/2026	TRDA Entrada Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
10/2/2026	CADL Candel Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/30/2026	ANNX Annexon	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$14.00 ➝ $15.00
9/21/2026	CADL Candel Therapeutics	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$12.00 ➝ $18.00
9/16/2026	TRDA Entrada Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/16/2026	AVTX Avalo Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/1/2026	ANNX Annexon	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$10.00 ➝ $14.00
8/31/2026	TRDA Entrada Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/17/2026	CADL Candel Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/14/2026	CADL Candel Therapeutics	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$9.00 ➝ $12.00
8/13/2026	TRDA Entrada Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 10/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANNX Annexon	N/A	N/A	N/A	N/A	$1.42 per share	N/A
AVTX Avalo Therapeutics	$60K	12,184.74	N/A	N/A	$4.49 per share	3.04
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	$0.95 per share	N/A
TRDA Entrada Therapeutics	$25.42M	8.63	N/A	N/A	$8.01 per share	0.70

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANNX Annexon	-$206.69M	-$1.16	N/A	N/A	N/A	N/A	-106.15%	-79.82%	11/9/2026 (Estimated)
AVTX Avalo Therapeutics	-$78.26M	-$4.37	N/A	N/A	N/A	N/A	-58.03%	-48.22%	11/5/2026 (Estimated)
CADL Candel Therapeutics	-$38.18M	-$1.41	N/A	N/A	N/A	N/A	-76.98%	-48.50%	11/12/2026 (Estimated)
TRDA Entrada Therapeutics	-$143.75M	-$3.96	N/A	N/A	N/A	-3,537.73%	-57.61%	-46.54%	11/5/2026 (Estimated)

Latest TRDA, ANNX, AVTX, and CADL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	AVTX Avalo Therapeutics	-$0.5946	N/A	N/A	N/A	N/A	N/A
11/5/2026	Q3 2026	TRDA Entrada Therapeutics	-$0.98	N/A	N/A	N/A	$2.13 million	N/A
8/13/2026	Q2 2026	CADL Candel Therapeutics	-$0.2379	-$0.52	-$0.2821	-$0.52	N/A	N/A
8/12/2026	Q2 2026	ANNX Annexon	-$0.2388	-$0.28	-$0.0412	-$0.28	$6.50 million	N/A
8/6/2026	Q2 2026	AVTX Avalo Therapeutics	-$0.5827	-$0.83	-$0.2473	-$0.83	N/A	N/A
8/5/2026	Q2 2026	TRDA Entrada Therapeutics	-$0.9738	-$1.01	-$0.0363	-$1.01	$2.32 million	$0.90 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANNX Annexon	N/A	N/A	N/A	N/A	N/A
AVTX Avalo Therapeutics	N/A	N/A	N/A	N/A	N/A
CADL Candel Therapeutics	N/A	N/A	N/A	N/A	N/A
TRDA Entrada Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANNX Annexon	N/A	5.53	5.53
AVTX Avalo Therapeutics	N/A	19.31	19.31
CADL Candel Therapeutics	0.38	16.09	16.09
TRDA Entrada Therapeutics	N/A	10.89	10.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANNX Annexon	N/A
AVTX Avalo Therapeutics	87.06%
CADL Candel Therapeutics	13.93%
TRDA Entrada Therapeutics	86.39%

Insider Ownership

Company	Insider Ownership
ANNX Annexon	10.31%
AVTX Avalo Therapeutics	4.46%
CADL Candel Therapeutics	14.30%
TRDA Entrada Therapeutics	9.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANNX Annexon	92	189.58 million	170.03 million	Optionable
AVTX Avalo Therapeutics	33	53.63 million	51.24 million	Not Optionable
CADL Candel Therapeutics	55	76.52 million	65.58 million	Optionable
TRDA Entrada Therapeutics	152	38.94 million	35.24 million	Optionable

TRDA, ANNX, AVTX, and CADL Headlines

Recent News About These Companies

Entrada Therapeutics (NASDAQ:TRDA) Stock Rating Lowered by Wall Street Zen

September 26, 2026 | marketbeat.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Receives Average Rating of "Moderate Buy" from Analysts

September 23, 2026 | marketbeat.com

Entrada Therapeutics, Inc.: Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program

September 10, 2026 | finanznachrichten.de

Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program

September 10, 2026 | globenewswire.com

Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Bioventures 2018 L.P. Mpm Sells 28,837 Shares of Stock

September 10, 2026 | insidertrades.com

Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $205,607.81 in Stock

September 9, 2026 | marketbeat.com

Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Bioventures 2018 L.P. Mpm Sells 38,500 Shares

September 9, 2026 | marketbeat.com

Bioventures 2018 L.P. Mpm Sells 192,500 Shares of Entrada Therapeutics (NASDAQ:TRDA) Stock

September 9, 2026 | marketbeat.com

Analysts Conflicted on These Healthcare Names: Definitive Healthcare Corp (DH) and Entrada Therapeutics Inc (TRDA)

September 5, 2026 | theglobeandmail.com

Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $180,691.89 in Stock

September 4, 2026 | insidertrades.com

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 2, 2026 | globenewswire.com

Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $26,168.33 in Stock

September 1, 2026 | insidertrades.com

Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $102,857.14 in Stock

August 27, 2026 | insidertrades.com

Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Ventures L.P. 5Am Sells 10,494 Shares of Stock

August 11, 2026 | insidertrades.com

Entrada Therapeutics Reports Second Quarter 2026 Financial Results

August 5, 2026 | finance.yahoo.com

Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Tops Revenue Estimates

August 5, 2026 | zacks.com

Insider Selling: Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Sells $11,768.30 in Stock

August 4, 2026 | insidertrades.com

Oppenheimer Remains a Buy on Entrada Therapeutics Inc (TRDA)

June 14, 2026 | theglobeandmail.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Pfizer (PFE)

June 9, 2026 | theglobeandmail.com

Entrada Therapeutics, Inc. (TRDA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

June 8, 2026 | seekingalpha.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Entrada Therapeutics, Inc. - TRDA

June 4, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRDA, ANNX, AVTX, and CADL Company Descriptions

Annexon NASDAQ:ANNX

$4.02 +0.02 (+0.50%)

Closing price 04:00 PM Eastern

Extended Trading

$4.11 +0.09 (+2.31%)

As of 07:50 PM Eastern

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Avalo Therapeutics NASDAQ:AVTX

$13.65 +0.22 (+1.64%)

Closing price 04:00 PM Eastern

Extended Trading

$13.64 -0.01 (-0.07%)

As of 07:30 PM Eastern

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Candel Therapeutics NASDAQ:CADL

$9.94 +0.28 (+2.90%)

Closing price 04:00 PM Eastern

Extended Trading

$10.04 +0.10 (+0.96%)

As of 07:30 PM Eastern

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Entrada Therapeutics NASDAQ:TRDA

$5.67 +0.14 (+2.53%)

Closing price 04:00 PM Eastern

Extended Trading

$5.66 0.00 (-0.09%)

As of 07:30 PM Eastern

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TRDA, ANNX, AVTX, and CADL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TRDA, ANNX, AVTX, and CADL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TRDA, ANNX, AVTX, and CADL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRDA, ANNX, AVTX, and CADL Company Descriptions

Annexon NASDAQ:ANNX

Avalo Therapeutics NASDAQ:AVTX

Candel Therapeutics NASDAQ:CADL

Entrada Therapeutics NASDAQ:TRDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TRDA, ANNX, AVTX, and CADL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TRDA, ANNX, AVTX, and CADL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TRDA, ANNX, AVTX, and CADL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRDA, ANNX, AVTX, and CADL Company Descriptions

Annexon NASDAQ:ANNX

Avalo Therapeutics NASDAQ:AVTX

Candel Therapeutics NASDAQ:CADL

Entrada Therapeutics NASDAQ:TRDA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools